Collegium Pharmaceutical Inc
COLL
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
50.3% downsideOvervalued by 50.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.14 Billion |
|---|---|
| Enterprise Value | $1.68 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.98 |
| Beta | 0.73 |
| Outstanding Shares | 32,087,472 |
Return
| Return on Equity | 23.99% |
|---|---|
| Return on Assets | 4.54% |
| Return on Invested Capital | 21.81% |
Valuation & Multiples
| P/E Ratio | 14.86 |
|---|---|
| PEG | 2.97 |
| Price to Sales | 1.46 |
| Price to Book Ratio | 3.89 |
| Enterprise Value to Revenue | 2.11 |
| Enterprise Value to EBIT | 6.34 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.48 |
| Debt to Equity | 2.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.37%▼ 118.38% |
|---|---|
| Total Invested | $15.93M▼ 98.73% |
| Investors Holding | 8▼ 258.00% |
ESG Score
No data
About Collegium Pharmaceutical Inc
CEO: Joseph Ciaffoni Relevant Senate Committees
Directly oversees the FDA, which regulates drug approvals, safety labeling, and manufacturing requirements for all Collegium products.
Oversees patent law and the DOJ; intellectual property is the core of Collegium's value, and DOJ oversight of controlled substances is a primary regulatory risk.
Frequent hearings on drug pricing and the opioid crisis create significant headline risk and influence legislative agendas that target pharmaceutical companies.
The VA is a massive purchaser of pain management medications; committee decisions on the VA national formulary directly affect Collegium's revenue.